Appropriate antibiotic use and why it is important: The challenges of bacterial resistance

Pediatric Infectious Disease Journal

Volumn 22, Issue 12, 2003, Pages 1143-1151

  Lieberman, Jay M ^a,b  

^a MILLER CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bacterial resistance; Fluoroquinolones; Linezolid; Quinupristin dalfopristin

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CHICKENPOX VACCINE; CHLORAMPHENICOL; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GATIFLOXACIN; INFLUENZA VACCINE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; METICILLIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOCOCCUS VACCINE; SULFONAMIDE; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CAMPYLOBACTER; CHICKENPOX; CHILD; COMMON COLD; CONFERENCE PAPER; DRUG INDICATION; ENTEROCOCCUS; GASTROENTERITIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IMMUNIZATION; INFECTION; INFECTION RISK; INFLUENZA; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEISSERIA GONORRHOEAE; NONHUMAN; OSTEOMYELITIS; OTITIS MEDIA; PEDIATRICIAN; PENICILLIN RESISTANCE; PHARYNGITIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SALMONELLA; SINUSITIS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TYPHOID FEVER; URINARY TRACT INFECTION; VIRUS INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; FEMALE; FLUOROQUINOLONES; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0346120094     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000101851.57263.63     Document Type: Conference Paper

References (65)

1. Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064-73.
2. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7:178-82.
3. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in children with no predisposing risk. JAMA 1998;279:593-8.
4. Fergie JE, Purcell K. Community-acquired methicillin-resistant Staphylococcus aureus infections in south Texas children. Pediatr Infect Dis J 2001;20:860-3.
5. Sattler CA, Mason EO Jr, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 2002;21:910-7.
6. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus: Minnesota and North Dakota, 1997-1999. MMWR 1999;48:707-10.
7. Martinez-Aguilar G, Hammerman W, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003;22:593-8.
8. Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002;21:530-4.
9. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917-24.
10. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-9.
11. American Academy of Pediatrics. Pneumococcal infections. In: Pickering LK, ed. Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003:490-500.
12. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance: a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis 1999;18:1-9.
13. American Academy of Pediatrics, Subcommittee on management of sinusitis and committee on quality improvement. Clinical practice guideline: management of sinusitis. Pediatrics 2001;108:798-808.
14. Leibovitz E, Piglansky L, Raiz S, Press J, Leiberman A, Dagan R. Bacteriologic and clinical efficacy of one day vs. three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children. Pediatr Infect Dis J 2000;19:1040-5.
15. Rice LB. Emergence of vancomycin-resistant enterococci. Emerg Infect Dis 2001;7:183-7.
16. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;1:57-8.
17. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342:710-21.
18. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.
19. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the uanA resistance gene. N Engl J Med 2003;348:1342-7.
20. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus: Pennsylvania, 2002. MMWR 2002;51:902.
21. McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescriptions in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis 2003;9:432-7.
22. Harrison CJ. Quinupristin/dalfopristin. Semin Pediatr Infect Dis 2001;12:200-10.
23. Dowzicky M, Talbot GH, Feger C, Prokocimer P, Etienne J, Leclercq R. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid®) during a worldwide clinical program. Diagn Microb Infect Dis 2000;37:57-62.
24. Rose CM, Reilly KJ, Haith LR, et al. Emergence of resistance of vancomycin-resistant Enterococcus faecium in a thermal injury patient treated with quinupristin-dalfopristin and cultured epithelial autografts for wound closure. Burns 2002;28:696-8.
25. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001;358:1975-82.
26. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002;346:867-9.
27. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-8.
28. Pai MP, Rodvold KA, Schreckenberger PC, Gonzales RD, Petrolatti JM, Quinn JP. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002;35:1269-72.
29. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003;9:1-9.
30. Kayser FH. The quinolones: mode of action and mechanism of resistance. Res Clinic Forums 1985;7:17-27.
31. Frieden TR, Mangi RJ. Inappropriate use of oral ciprofloxacin. JAMA 1990;264:1438-40.
32. Centers for Disease Control and Prevention. Fluoroquinolone-resistance in Neisseria gonorrhoeae, Hawaii, 1999, and decreased susceptibility to azithromycin in N. gonorrhoeae, Missouri, 1999. MMWR 2000;49:833-7.
33. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR 2002;51(RR-6):36-42.
34. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347-82.
35. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada: Canadian Bacterial Surveillance Network. N Engl J Med 1999;341:233-9.
36. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50.
37. Kays MB, Smith DW, Wack ME, Denys GA. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 2002;22:395-9.
38. Smith KE, Besser JM, Hedberg CW, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. N Engl J Med 1999;340:1525-32.
39. Nachamkin I, Ung H, Li M. Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA, 1982-2001. Emerg Infect Dis 2002;8:1501-3.
40. Chiu CH, Wu TL, Su LH, et al. The emergence in Taiwan of fluoroquinolone resistance in Salmonella enterica serotype choleraesuis. N Engl J Med 2002;346:413-9.
41. Hakanen A, Koitlainen P, Huovinen P, Helenius H, Siitonen A. Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia. Emerg Infect Dis 2001;7:996-1003.
42. Tollefson L, Miller MA. Antibiotic use in food animals: controlling the human health impact. J AOAC Int 2000;83:245-54.
43. Velazquez JB, Jimenez A, Chomon B, Villa TG. Incidence and transmission of antibiotic resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother 1995;35:]173-8.
44. Center for Science in the Public Interest. Protecting the crown jewels of medicine: a strategic plan to preserve the effectiveness of antibiotics. Washington, DC, 1998. [Center for Science in the Public Interest web site]. Available at http://www.cspinet.org/reports/abiotic.htm. Accessed August 27, 2003.
45. Department of Health and Human Services, Food and Drug Administration. HHS response to House Report 106-157: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, appropriations bill, 2000. Human-use antibiotics in livestock production. [Center for Veterinary Medicine web site]. Available at http://www.fda.gov/ cvm/antimicrobial/HRESP106_157.htm#execsummary. Accessed August 28, 2003.
46. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998;338:1405-12.
47. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2003;52 (RR-8):7-10.
48. Craig WA. Does the dose matter? Clin Infect Dis 2001;33(Suppl 3):S233-7.
49. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998;279:365-70.
50. Schrag SJ, Peña C, Fernández J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 2001;286:49-56.
51. Levy SB. Antibiotic resistance: consequences of inaction. Clin Infect Dis 2001;33(Suppl 3):S124-9.
52. Kozyrskyj AL, Hildes-Ripstein GE, Longstaffe SE, et al. Treatment of acute otitis media with a shortened course of antibiotics: a meta-analysis. JAMA 1998;279:1736-42.
53. Centers for Disease Control and Prevention. Multidrug-resistant Streptococcus pneumoniae in a child care center: southwest Georgia, December 2000. MMWR 2002;50:1156-8.
54. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997;337:441-6.
55. Ekdahl K, Ahlinder I, Hansson HB, et al. Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project. Clin Infect Dis 1997;25:1113-7.
56. Enne VI, Livermore DM, Stephens P, Hall LM. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 2001;357:1325-8.
57. American Academy of Pediatrics. Appropriate use of antimicrobial agents. In: Pickering LK, ed. Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2003:695-7.
58. Nyquist AC, Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA 1998;279:875-7.
59. Watson RL, Dowell SF, Jayaraman M, Keyserling H, Kolczak M, Schwartz B. Antimicrobial use for pediatric upper respiratory infections: reported practice, actual practice, and parent beliefs. Pediatrics 1999;104:1251-7.
60. Bauchner H, Pelton SI, Klein JO. Parents, physicians, and antibiotic use. Pediatrics 1999;103:395-401.
61. Avorn J, Solomon DH. Cultural and economic factors that (mis)shape antibiotic use: the nonpharmacologic basis of therapeutics. Ann Intern Med 2000;133:128-35.
62. Finkelstein JA, Davis RL, Dowell SF, et al. Reducing antibiotic use in children: a randomized trial in 12 practices. Pediatrics 2001;108:1-7.
63. Belongia EA, Sullivan BJ, Chyou PH, Madagame E, Red KD, Schwartz B. A community intervention trial to promote judicious antibiotic use and reduce penicillin-resistant Streptococcus pneumoniae carriage in children. Pediatrics 2001;108:575-83.
64. McCaig LF, Besser RE, Hughes JM. Trends in antimicrobial prescribing rates for children and adolescents. JAMA 2002;287:3096-102.
65. Halasa NB, Griffin MR, Zhu Y, Edwards KM. Decreased number of antibiotic prescriptions in office-based settings from 1993 to 1999 in children less than five years of age. Pediatr Infect Dis J 2002;21:1023-8.